Navigation Links
ALIMTA Helped Keep Most Common Form of Lung Cancer at Bay In Elderly Patients
Date:9/26/2011

INDIANAPOLIS, Sept. 26, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that a new subgroup analysis of data from the pivotal Phase III PARAMOUNT study showed that continuation maintenance therapy with ALIMTA® (pemetrexed for injection) also reduces the risk of disease progression in patients aged 70 years or older with advanced nonsquamous non-small cell lung cancer (NSCLC), the most common type of lung cancer.

Results from the new analysis were presented during the Lung Cancer – Metastatic Poster Session (Abstract #9072) at the 2011 European Multidisciplinary Cancer Congress (formerly known as the ECCO-ESMO Cancer Congress) in Stockholm, Sweden.

PARAMOUNT is the first study to evaluate the use of continuation maintenance therapy with ALIMTA following first-line ALIMTA plus cisplatin therapy. A total of 939 patients with advanced nonsquamous NSCLC were enrolled in the study; 539 did not progress during the induction phase and entered the maintenance phase of the trial. Of those, 92 patients were elderly.

The new analysis compared ALIMTA to placebo in elderly patients aged greater than or equal to 70 years (n=92). In the group of elderly patients, ALIMTA reduced the risk of disease progression by 65 percent (hazard ratio, 0.35; 95% CI: 0.20–0.63), based on a median progression-free survival of 6.4 months on the ALIMTA arm compared with 3.0 months on the placebo arm. In the group of patients less than 70 years of age, ALIMTA reduced the risk of disease progression by 31 percent (hazard ratio, 0.69, 95% CI: 0.54–0.90), with a progression-free survival of 4.0 months for ALIMTA and 2.8 months for placebo.

"Lung cancer can be challenging to treat in patients over 70 years of age because they often have comorbidities and may be less tolerant of anti-cancer therapies," said Cesare Gridelli, M.D., '/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
2. OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
3. U.S. District Court Rules from Bench in Lillys Favor, Confirms Validity of Alimta Patent
4. Lung Cancer Study Reveals Similar Outcomes for African-American and Caucasian Patients Treated With Alimta®
5. ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for Deadly Form of Lung Cancer
6. Study Shows Lantus(R) Helped People Living with Type 2 Diabetes Reach the ADAs Recommended Target for Blood Sugar Control
7. Whistleblower Doctor Comments on His Case that Helped Expose Illegal Marketing of Topamax
8. UT Southwestern Doctors Expertise Helped Trapped Chilean Miners During Pressured Half-Mile-Deep Rescue
9. Cintas ReviveR AEDs Helped Save Over 50 Lives at LA Fitness Facilities
10. Endoscopy Identified as Safe and Effective Method in Treating Common Complication of Gastric Bypass Surgery
11. Genetics Determine Optimal Drug Dose of Common Anticoagulant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... BioRx, a Diplomat company (NYSE: DPLO ) announced that ... based on a survey held region-wide. The survey ... Philadelphia -based research firm called Workplace Dynamics. The ... across the Greater Cincinnati and ... workplace environment to overall organizational health. Once the surveys were ...
(Date:7/7/2015)... NEW YORK , July 7, 2015 /PRNewswire/ ... Welch Allyn for $2 billion in cash and ... competitive patient monitoring market, according to Kalorama Information. ... heretofore participated in the medical device and advanced ... maker of hospital beds, patient lifting devices, and ...
(Date:7/7/2015)... 2015   ICD-10 Charts ( www.icd10charts.com ) ... it has officially launched its newest line of ... and the new 4 Step ICD-10 Implementation Plan.  ... other ICD-10 Charts resources and mobile apps, are ... free-of-charge.  With the release of these resources, the ...
Breaking Medicine Technology:BioRx Named a Top Workplace in 2015 by Enquirer Media 2BioRx Named a Top Workplace in 2015 by Enquirer Media 3Kalorama: Hill-Rom Enters Monitoring Market with Welch Allyn Purchase 2Kalorama: Hill-Rom Enters Monitoring Market with Welch Allyn Purchase 3ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 2ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 3ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 4
... 2007 /PRNewswire/ -- A new Harris Poll,suggests that the ... effective than the vaccines used in some previous years. ... only 24 percent,less likely to get the flu than ... two previous Harris Polls on the same,topic.(1) In the ...
... study showed significant,results in favor of alemtuzumab versus ... 2007,/PRNewswire-FirstCall/ -- Genzyme Corporation and Bayer HealthCare,Pharmaceutical today ... study. This interim analysis of all patient data,through ... the study for,all patients showed that a once-yearly ...
Cached Medicine Technology:Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 2Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 3Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 4Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 5Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 6Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 2Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 3Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 4Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 5Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 6Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 7Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 8Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 9
(Date:7/7/2015)... Los Angeles, CA (PRWEB) , ... July 07, ... ... the International Business Times highlights rumors about possible facial rejuvenation that have emerged ... 67 year-old former U.S. Secretary of State looks more youthful than she has ...
(Date:7/7/2015)... , ... July 07, 2015 , ... Greatist ... and website that helps active people find the most fun activities to do with ... coverage for millennials. It also increases Greatist’s opportunity for events, e-commerce, and brand partnerships. ...
(Date:7/7/2015)... ... July 07, 2015 , ... Illinois cannabis cultivation centers ... to permit holders. The Medical Cannabis Alliance of Illinois’ (MCAI) board and its ... are committed to making sure patients have access to cannabis as a viable ...
(Date:7/7/2015)... ... 07, 2015 , ... At the end of June Pacific Prime Renewals team in Hong Kong ... initiative, spearheaded by the Renewals Manager, Danielle Cotton, aims to not only reduce but eventually ... initiative Cotton explained, “We send anything between 300 and 600 pieces of paper per month. ...
(Date:7/7/2015)... , ... July 07, 2015 , ... ... further enhance the experience for its patient community using its IDF ePHR, an ... patients with primary immunodeficiency diseases (PI) to easily track their health information, including ...
Breaking Medicine News(10 mins):Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 2Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 3Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2Health News:Cannabis Growers and Dispensaries Form Medical Cannabis Alliance of Illinois 2Health News:Pacific Prime Hong Kong Renewals Team Starts Push to go Green 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3
... the common diarrhea-causing disease , WEDNESDAY, Jan. 27 (HealthDay ... lives of millions of children in developing nations who ... studies show. , A study conducted in Malawi and ... life-threatening rotavirus in infants by more than 61 percent. ...
... ... cancer charity partners with the Vehicle Donation Processing Center to provide financial assistance to ... ... has partnered with the Vehicle Donation Processing Center, Inc. to launch a vehicle and ...
... NEWTOWN, Pa. , Jan. 27 CONNEXION ... Rob Naticchia as Executive Vice President, Client Services. In ... and development of CXHC, including its Clinical CONNEXION and Publication ... 15 years of pharmaceutical marketing and sales experience.  Most recently, ...
... , , ... the poorest nation in the Western Hemisphere.  It has practically nothing.  Although ... stationed where the quake hit the hardest. , Orphans International Worldwide Haiti ... Province, survived the earthquake unscathed.  An upcoming benefit in New York ...
... Adults with chronic rhinosinusitis a debilitating inflammation of the ... back report significantly improved quality of life following ... study led by Oregon Health & Science University (OHSU). ... Otolaryngology Head and Neck Surgery . ...
... ... a devastating magnitude-7.0 earthquake rocked Haiti, the global humanitarian organization Save the Children has ... , ... January 27, 2010 -- Two weeks after a devastating magnitude-7.0 earthquake rocked Haiti, the ...
Cached Medicine News:Health News:Rotavirus Vaccine Could Save Millions of Children Worldwide 2Health News:Rotavirus Vaccine Could Save Millions of Children Worldwide 3Health News:Rotavirus Vaccine Could Save Millions of Children Worldwide 4Health News: The Breast Cancer Society Launches Vehicle Donation Program 2Health News: The Breast Cancer Society Launches Vehicle Donation Program 3Health News:Robert Naticchia Joins CONNEXION Healthcare as Executive Vice President, Client Services 2Health News:Orphans International Worldwide Haiti Near Jacmel to Grow After Earthquake 2Health News:Orphans International Worldwide Haiti Near Jacmel to Grow After Earthquake 3Health News:Orphans International Worldwide Haiti Near Jacmel to Grow After Earthquake 4Health News:Orphans International Worldwide Haiti Near Jacmel to Grow After Earthquake 5Health News:Surgery helps chronic sinusitis sufferers get relief 2Health News:Two Weeks After Haiti Quake, Save the Children Helps More Than 105,000 Children and Families with Food, Medicines, Basic Supplies 2Health News:Two Weeks After Haiti Quake, Save the Children Helps More Than 105,000 Children and Families with Food, Medicines, Basic Supplies 3
Slick® Disposable Endotracheal Stylet, Nylon-coated wire, Malleable core, Sureloc Stop helps maintain desired length for patient safety. Handle forming capability for better grip. Sterile. Single...
... Requires minimal cervical spine manipulation. Prevent ... or nasally. Cost effective alternative to X-ray. ... of the soft tissues in the neck. ... location of the trachea relative to the ...
... Aaron manufactures two groups of flexible lighting ... and non-sterile in three different sizes 5", ... shaft portion of the light). These lights ... light is needed., ,The second group ...
... manufactures two groups of flexible lighting products. ... non-sterile in three different sizes 5", 10", ... portion of the light). These lights are ... is needed., ,The second group of ...
Medicine Products: